Floatz logo

Ny-Eso-1 Reactive Tcr Retroviral Vector Transduced Autologous Pbl

Unspecified Adult Solid Tumor, Protocol Specific

Jonsson Comprehensive Cancer CenterCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Unspecified Adult Solid Tumor, Protocol Specific cohort.

Asset / SponsorPhaseRating
Amifostine
M.D. Anderson Cancer Center
Phase 4BBB
NEPENTHE
M.D. Anderson Cancer Center
Phase 4BBB
DEXAMETHASONE
Alliance for Clinical Trials in Oncology
Phase 3BBB
ETOPOSIDE
University of California, Davis
Phase 2/3BBB
FILGRASTIM
National Institutes of Health Clinical Center (CC)
Phase 3BBB

View all 50 →

Same molecule, other indications

Ny-Eso-1 Reactive Tcr Retroviral Vector Transduced Autologous Pbl is also rated in:

Adult Solid NeoplasmDormant
CC
Indicative ·
47 / 100
View asset →
Childhood Solid NeoplasmDormant
CC
Indicative ·
47 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →